What is decapeptide-12?

A synthetic peptide of ten amino acids, 1,395.5 g/mol, sold as a brightening ingredient for melasma and dark spots under the trade name Lumixyl. Its claimed mechanism is inhibition of tyrosinase, the enzyme that makes melanin — the same target as hydroquinone, which it was developed to replace.

Is decapeptide-12 the same as Lumixyl?

Yes. PubChem records Lumixyl as a synonym of decapeptide-12, and the clinical papers describe the same system either way — a 0.01% peptide cream used with an antioxidant cleanser, a 20% glycolic acid lotion and a sunscreen. Some papers call the ingredient decapeptide-12 and some call it a proprietary oligopeptide, which is why a search on one name misses the other.

Does decapeptide-12 work for melasma?

The only randomized trial found improvement in all five women it enrolled, using the peptide cream on one side of the face and a placebo on the other. Five people is a pilot. Every later clinical report added glycolic acid, an antioxidant cleanser and a sunscreen, has no control group, and so cannot tell how much of the improvement came from the peptide. Glycolic acid and sunscreen each have their own literature in melasma.

Is decapeptide-12 safer than hydroquinone?

The papers report it was well tolerated, with no irritation or allergy in the small groups studied, and describe it as lacking hydroquinone's cytotoxicity in laboratory tests. None of the indexed trials compared the two head to head in people, so a relative safety claim rests on laboratory data and on tolerability in groups of five to thirty-three.

Who did the research?

Mostly one research team. B. M. Hantash, who describes the oligopeptide in the 2009 paper, is first author of the only randomized trial and the 2012 case report and last author of the 2014 report, and appears on the 2021 penetration study under a company affiliation. The 2013 Colombian study is by a separate group. That concentration is common for a proprietary ingredient; it is also why the file has no independent replication.

How is it different from nonapeptide-1 and tetrapeptide-30?

Each brightening peptide claims a different step. Decapeptide-12 is claimed to inhibit tyrosinase directly; nonapeptide-1 to block the hormone signal that tells pigment cells to make melanin; tetrapeptide-30 to reduce the signals skin cells send after UV exposure. Tetrapeptide-30 is the only one of the three near the 500-dalton line; decapeptide-12 is the heaviest.

Decapeptide-12: The Lumixyl Peptide, and a Record Mostly Written by Its Inventor

The brightening peptide sold as Lumixyl has one randomized trial — five women, split-face — and every other clinical report tests a four-product system in which the peptide is one part. What each study tested, and who ran it.

Decapeptide-12 is a brightening peptide sold for melasma and dark spots, often under its trade name, Lumixyl. Its papers present it as a route to the enzyme hydroquinone targets without hydroquinone's toxicity. Its clinical file is seven records long, and reading them in order shows a pattern: one small randomized trial of the peptide, then several reports of a system in which the peptide is one of four products.

The molecule, under both names

PubChem CID 25087629: formula C65H90N18O17, 1,395.5 g/mol, ten residues. PubChem lists Lumixyl as a synonym of the same record, which matters because the literature splits between the two names.

At 1,395.5 g/mol the peptide is about 2.8 times the 500-dalton figure usually quoted as the practical ceiling for passive movement across intact stratum corneum. Pigment is made in melanocytes at the base of the epidermis. Among the brightening peptides this site covers it is the heaviest: tetrapeptide-30 is 500.6 and nonapeptide-1 1,206.5.

Seven records, split between two names

Searched on 2026-09-21, with a control query validated in the same session:

Search (title/abstract)	Records	What they are
`decapeptide-12`	4	two open-label system studies, one post-inflammatory hyperpigmentation report, one penetration study
`Lumixyl`	3	the randomized pilot, a case study, and a 2018 night-cream trial that does not name the peptide in its abstract

The randomized trial — the one piece of evidence that isolates the peptide — is indexed under Lumixyl and describes the active as "a proprietary oligopeptide". A search on the INCI name alone never finds it.

The one randomized trial: five women, one side of the face each

Hantash and Jimenez, Journal of Drugs in Dermatology 2009, was a split-face, double-blind, placebo-controlled pilot. Five women with Fitzpatrick phototype IV and moderate, recalcitrant melasma applied 0.01% oligopeptide cream twice daily to one side of the face and placebo to the other for 16 weeks. Improvement was graded on 10-point and five-point scales. All five showed statistically significant improvement in melasma and overall facial appearance, with no visible irritation or allergy.

The design is the right one for a pigment treatment: each woman is her own control, which removes differences in skin type, sun exposure and season. The size is a pilot's. The authors call it that, and say the peptide "warrants further evaluation". The indexed record contains no larger randomized trial of the peptide on its own since. The one later randomized trial found under the trade name — Jiang and colleagues, Journal of Clinical and Aesthetic Dermatology 2018, funded by the product's maker — compared a multi-action night cream against no night cream in 25 completers, and its abstract does not name the peptide at all.

After 2009: a system, not a peptide

Every later report that names the peptide tests a four-product regimen:

Kassim, Hussain and Goldberg, Journal of Cosmetic and Laser Therapy 2012 — decapeptide-12 with an antioxidant cleanser, a glycolic-acid moisturiser and a broad-spectrum sunscreen, open-label, 15 women with photodamage, 13 completing 24 weeks. 38.5% went from moderate photodamage to cleared on the global scale.
Hantash and Jimenez, Journal of Drugs in Dermatology 2012 — the Lumixyl Topical Brightening System (0.01% oligopeptide cream, antioxidant cleanser, 20% glycolic acid lotion, physical sunscreen), a case study in which all patients improved and one of four cleared at six weeks.
Ramírez and colleagues, Journal of Drugs in Dermatology 2013 — the same four products, open-label and multicentre, 33 Hispanic women with mild-to-moderate melasma for 16 weeks. Mean MASI fell 36%, 46%, 54% and 60% at weeks 4, 8, 12 and 16, with no adverse events.
Bhatia, Hsu and Hantash, Journal of Drugs in Dermatology 2014 — topical decapeptide-12 combined with a dermal-infusion device for post-inflammatory hyperpigmentation in skin of colour. The indexed record has no abstract.

None of these has a control group. All of them add at least two ingredients with their own evidence for pigmentation — 20% glycolic acid, an exfoliant, and daily broad-spectrum sunscreen. A 60% MASI drop in women using all four products is a result about the regimen. It cannot be divided among its parts, and the reports do not try.

This is the same shape as the single randomized trial behind nonapeptide-1, where a peptide shared its arm with four other components including a sunscreen. It is the commonest way a brightening peptide acquires a clinical reputation.

Who wrote the file

B. M. Hantash is first author of the 2009 randomized pilot and the 2012 case study, last author of the 2014 report, and an author of the 2021 penetration study, where he is listed at Escape Therapeutics. The 2009 paper describes the oligopeptide as having been "previously shown" to inhibit tyrosinase. Only the 2012 photodamage study and the 2013 Colombian study list no author from that group.

Inventor-led research is normal for a proprietary ingredient and says nothing about whether the results are correct. It does mean the file has no independent replication of the randomized result, and that the only work outside the group tested the four-product system rather than the peptide.

The penetration problem, stated by the ingredient's own researchers

Chen and colleagues, International Journal of Pharmaceutics 2021, with Hantash as co-author, state plainly that decapeptide-12 "suffers from limited transcutaneous penetration due to its hydrophilicity and high molecular weight". They made a palmitoylated version — the fatty-acid modification behind palmitoyl tripeptide-1 and most "palmitoyl" peptides — and found it stayed in excised human skin better. Microneedles improved delivery of the unmodified peptide; chemical penetration enhancers did not.

That paper also describes decapeptide-12 as achieving "efficacy up to more than 50% upon 16 weeks of twice-daily treatment". In the indexed record the only 16-week figure above 50% is the 60% MASI fall in the four-product system study — not a result of the peptide alone.

What this supports saying

Decapeptide-12 and Lumixyl are the same molecule, 1,395.5 g/mol, far above the usual penetration threshold, and its own researchers call its penetration limited.
The only randomized trial of the peptide enrolled five women and found improvement on every treated side.
Every later clinical report tested a four-product system including glycolic acid and sunscreen, without a control group.
Most of the file comes from one inventor's group, and the randomized result has not been independently repeated.

Where to go next

Nonapeptide-1 — the melanin-signal peptide, and a single trial that missed significance.
Tetrapeptide-30 — the smallest brightening peptide, and the only one tested in an arm of its own against a vitamin C derivative.
How to read a peptide ingredient list — why 0.01% sits far below the one-percent line on a label.
Peptides for skin: the whole category, counted — the census this entry sits in.